Huntington National Bank Raises Stock Position in Zoetis Inc. (NYSE:ZTS)

Huntington National Bank lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,157 shares of the company’s stock after acquiring an additional 284 shares during the quarter. Huntington National Bank’s holdings in Zoetis were worth $522,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Sound View Wealth Advisors Group LLC increased its position in shares of Zoetis by 1.5% during the third quarter. Sound View Wealth Advisors Group LLC now owns 4,043 shares of the company’s stock worth $669,000 after acquiring an additional 60 shares during the period. Seeyond boosted its stake in shares of Zoetis by 0.9% during the third quarter. Seeyond now owns 6,965 shares of the company’s stock valued at $1,152,000 after purchasing an additional 65 shares in the last quarter. Tarbox Family Office Inc. boosted its stake in shares of Zoetis by 29.4% during the third quarter. Tarbox Family Office Inc. now owns 295 shares of the company’s stock valued at $49,000 after purchasing an additional 67 shares in the last quarter. Equitable Holdings Inc. boosted its stake in shares of Zoetis by 2.3% during the third quarter. Equitable Holdings Inc. now owns 2,977 shares of the company’s stock valued at $492,000 after purchasing an additional 67 shares in the last quarter. Finally, Harfst & Associates Inc. boosted its stake in shares of Zoetis by 3.2% during the third quarter. Harfst & Associates Inc. now owns 2,190 shares of the company’s stock valued at $362,000 after purchasing an additional 68 shares in the last quarter. 92.50% of the stock is currently owned by institutional investors and hedge funds.

NYSE ZTS opened at $161.95 on Thursday. The company has a fifty day simple moving average of $162.28 and a two-hundred day simple moving average of $158.16. The stock has a market cap of $76.97 billion, a P/E ratio of 48.06, a P/E/G ratio of 4.35 and a beta of 0.71. Zoetis Inc. has a 12-month low of $90.14 and a 12-month high of $176.64. The company has a current ratio of 3.47, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 5th. The company reported $1.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.19. The business had revenue of $1.79 billion during the quarter, compared to analysts’ expectations of $1.63 billion. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the company posted $0.94 earnings per share. As a group, sell-side analysts forecast that Zoetis Inc. will post 3.63 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 1st. Investors of record on Wednesday, January 20th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Tuesday, January 19th. This is a boost from Zoetis’s previous quarterly dividend of $0.20. Zoetis’s dividend payout ratio (DPR) is 21.98%.

In related news, EVP Heidi C. Chen sold 1,179 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $161.43, for a total transaction of $190,325.97. Following the completion of the transaction, the executive vice president now owns 17,514 shares of the company’s stock, valued at $2,827,285.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Heidi C. Chen sold 1,180 shares of the firm’s stock in a transaction on Tuesday, December 1st. The stock was sold at an average price of $161.64, for a total transaction of $190,735.20. Following the transaction, the executive vice president now directly owns 17,515 shares of the company’s stock, valued at approximately $2,831,124.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 110,606 shares of company stock valued at $18,241,735. 0.17% of the stock is currently owned by corporate insiders.

A number of equities analysts have recently issued reports on the stock. Morgan Stanley increased their price objective on shares of Zoetis from $167.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, November 13th. Atlantic Securities assumed coverage on shares of Zoetis in a research note on Monday, September 21st. They set an “overweight” rating and a $191.00 price objective on the stock. BidaskClub upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Thursday, December 31st. Truist increased their price objective on shares of Zoetis from $160.00 to $170.00 in a research note on Thursday, November 12th. Finally, Barclays raised their target price on shares of Zoetis from $175.00 to $189.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $161.14.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: What is meant by buying and selling pressure?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.